Individual is a model and not a real patient.

WHO IS THE APPROPRIATE FORXIGA TYPE 1 DIABETES (T1D) PATIENT?1

  • Adults without diabetic ketoacidosis (DKA) risk factors
  • Adults with normal ketone levels at Forxiga initiation
  • Adults who are insufficiently controlled on optimised insulin therapy alone
  • Adults who are knowledgeable and committed to managing T1D
  • Adults who are able and willing to monitor ketone levels and blood glucose when necessary
  • Adults with a BMI of ≥27 kg/m2

Treatment with Forxiga 5 mg is to be initiated and supervised by specialists in T1D. Forxiga should not be initiated in patients with a glomerular filtration rate (GFR) <60 mL/min and should be discontinued at GFR persistently below 45 mL/min.1

PATIENT CASE STUDY TOOL

Important safety information for healthcare professionals to minimise the risk of DKA can be found in the Risk Minimisation Materials. Available below:

RISK MINIMISATION MATERIALS

Country HCP materials Patient materials
Austria VIEW VIEW
Belgium Dutch VIEW VIEW
Belgium French VIEW VIEW
Belgium German Not applicable VIEW
Bulgaria VIEW VIEW
Croatia VIEW VIEW
Cyprus Forxiga is not currently available for T1D
Czech Republic VIEW VIEW
Denmark VIEW VIEW
Estonia VIEW VIEW
Finland Finnish VIEW VIEW
Finland Swedish VIEW VIEW
Germany VIEW VIEW
Greece Please contact AstraZeneca Medical Information & Patient Safety department in Greece for materials via phone by calling +30 210 6871 500
Hungary VIEW VIEW
Iceland VIEW VIEW
Ireland VIEW VIEW
Italy VIEW VIEW
Latvia VIEW VIEW
Lithuania VIEW VIEW
Luxemburg VIEW VIEW
Malta VIEW VIEW
Netherlands VIEW VIEW
Norway VIEW VIEW
Poland VIEW VIEW
Portugal Forxiga is not currently available for T1D
Romania VIEW VIEW
Slovakia Forxiga is not currently available for T1D (i.e. 5 mg dose)
Slovenia Forxiga is not currently available for T1D
Spain Forxiga is not currently available for T1D
Sweden VIEW VIEW

FORXIGA T1D EFFICACY

References:

  1. Forxiga. Summary of Product Characteristics. 2019. AstraZeneca.
 

Loading......